Figures
Abstract
Background
Low back pain is the leading cause of disability worldwide. Although numerous treatment approaches are recommended by international clinical guidelines, there is still limited understanding of which interventions provide the best value for money. We aimed to critically appraise and summarise the evidence on the cost-effectiveness and costs of interventions endorsed in recent guidelines to manage low back pain (LBP), compared to usual care.
Methods and findings
We searched 10 electronic databases (e.g., MEDLINE (OvidSP), EMBASE (OvidSP), PsycINFO (OvidSP)) from inception to 9th of February 2026 for cost-effectiveness studies of guideline-recommended treatments to manage non-specific LBP. The primary outcome was cost/quality-adjusted life year (QALY), which was converted to 2024 Great British Pound values, tabulated and summarised qualitatively. Secondary outcomes were direct costs (total, interventional, health service use, community services and out-of-pocket costs) and indirect costs (e.g., lost wages, lost productivity, absenteeism). We assessed methodological quality using the Consensus Health Economics Criteria (CHEC) checklist for within-trial economic evaluations or the Philips checklist for modelling studies. Our review included 20 studies (17 within-trial economic evaluations and three modelling studies), published between 2005 and 2026. Half (n = 10) focussed on chronic LBP (>3-month duration), and eight included mixed populations (i.e., acute, subacute and chronic). All studies were of non-pharmacological, non-surgical interventions, both single-modality and multimodal interventions (e.g., exercise plus spinal manipulation; diet plus physical activity). Most interventions are cost-effective at a willingness-to-pay threshold of £20,000. Moreover, interventions aiming to reduce fear and stress or support self-management in people with chronic LBP, as well as clinician-delivered interventions including yoga, acupuncture, cognitive therapy and self-management support are potentially cost-saving from the healthcare, societal and payer’s perspectives, as they are both more effective and less costly than usual care (e.g., first contact management, including advice and medication). All of the evidence is derived from high-income countries, and from a considerable heterogenous body of literature. Evidence on cost-effective treatments in low- and middle-income countries remains limited.
Conclusions
Non-pharmacological, non-surgical interventions that include education, psychological support, acupuncture and exercise seem to be cost-effective for managing LBP, compared to usual care. Improved access to and implementation of these effective treatments is urgently needed so more people can benefit from them in routine care.
Author summary
Why was this study done?
- Low back pain is the leading cause of disability worldwide, affecting millions of people and placing a major financial burden on individuals, healthcare systems, and society.
- Many invasive and non-invasive treatments are recommended for low back pain, but understanding which options provide the best value for money is important for healthcare funding and policy decisions.
- Previous reviews have focussed on specific treatments only, whereas a broader assessment of the cost-effectiveness of all available low back pain interventions can better inform decision-makers.
What did the researchers do and find?
- We reviewed all economic evaluations of treatments endorsed by international clinical practice guidelines.
- Several non-drug treatments, such as yoga, acupuncture, physical therapies, and psychological therapies, significantly improve outcomes while also reducing costs compared with usual care.
- Combined treatment approaches—including exercise paired with manual therapy, cognitive behavioural therapy, or dietary interventions—were good value treatments for people with persistent low back pain.
What do these findings mean?
- These findings suggest that investing in effective non-surgical and multidisciplinary care can improve health outcomes while making efficient use of healthcare resources.
- The priority now is to increase access to and implementation of these effective treatments so more people can benefit from them in routine care.
- Most evidence comes from high-income countries, and therefore the relevance of our findings for populations of low- and middle-income settings is unknown.
Citation: Mathieson S, Underwood M, Ibrahim M, Hua Z, Zhu Z, Ferreira PH, et al. (2026) Cost-effectiveness of recommended interventions for managing low back pain: A systematic review. PLoS Med 23(10): e1005273. https://doi.org/10.1371/journal.pmed.1005273
Academic Editor: Christelle Nguyen, Université Paris Cité UFR de Médecine: Universite Paris Cite UFR de Medecine, FRANCE
Received: April 2, 2026; Accepted: September 18, 2026; Published: October 27, 2026
Copyright: © 2026 Mathieson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting information files.
Funding: The author(s) received no specific funding for this work.
Competing interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests: SM, MI, ZH, ERA, AB and JE report no conflicts of interest. MU is a chief investigator or co-investigator on multiple previous and current research grants from the UK National Institute for Health Research, and is a co-investigator on grants funded by the Australian NHMRC and Norwegian Research Council. He is a director and shareholder of Clinvivo Ltd, which provides electronic data collection for health services research and has accepted honoraria for examining theses and performing peer review. He receives some salary support from University Hospitals Coventry and Warwickshire. He is a co-investigator on two current and one completed NIHR-funded studies that have, or have had, additional support from Stryker Ltd. He has accepted travel expenses and accommodation from the organisers for speaking at academic meetings. He has published multiple papers on back pain, including health economic analyses, some of which are cited here. HM is a member of the UK NIHR HTA Funding Committee. JLB is supported by an unrestricted Fellowship from Haleon Australia, which has no relationship to this project. DJH provides consulting advice on scientific advisory boards for Haleon, TLCBio, Novartis, Tissuegene, Sanofi, and Enlivex. DJH is the editor of the osteoarthritis section for UpToDate and co-Editor-in-Chief of Osteoarthritis and Cartilage. DJH is supported by a National Health and Medical Research Council of Australia Investigator Grant. PHF has been funded by VIATRIS Medical Affairs to conduct independent work on the safety of anti-inflammatory drugs for pain. MLF has provided expert opinion to the Advisory Boards of VIATRIS and Haleon. MLF is supported by a National Health and Medical Research Council of Australia Investigator Grant.
Abbreviations: BEST, Back Skills Training; CBT, Cognitive Behavioral Therapy; CEA, Cost-effectiveness Analysis Registry; CFT, Cognitive Functional Therapy; CHEC, Consensus Health Economics Criteria; CHEERS, Consolidated Health Economics Evaluation Reporting Standards; CI, confidence intervals; CPI, Consumer Price Index; FREE, Fear Reduction Exercised Early; GBP, Great British Pound; GDP, Gross Domestic Product; GP, general practitioner; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HTA, Health Technology Assessment; ICER, incremental cost-effectiveness ratio; LBP, low back pain; MBR, multidisciplinary biopsychosocial rehabilitation; MBSR, Mindfulness-Based Stress Reduction; NASS, North American Spine Society; NICE, National Institute for Health and Care Excellence; PPP, Purchasing Power Parity; PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses; QALY, quality-adjusted life year; USD, United States Dollar; WHO, World Health Organization; WTP, Willingness to pay
Background
Low back pain (LBP) is the leading cause of years lived with disability globally [1]. The economic impact of LBP extends beyond the direct healthcare system costs to affect individuals, employers, health and social care systems and society. The average annual direct and indirect costs (e.g., work absenteeism) are substantial [2]. For instance, in Australia, ~$3.4 billion (~Great British Pound [GBP]1.7 billion) was spent on direct health costs for managing back problems in 2020/21, equating to 2.2% of Australia’s total health system expenditure [3]. A 2023 meta-analysis of the global economic burden of LBP determined that the pooled annual direct and total (i.e., direct plus indirect) costs of LBP per patient were United States Dollar (USD) 9,231 (GBP 6,994) and USD 10,143 (GBP 7,685), respectively [2].
Many interventions that can be delivered by a range of health workers are available to manage LBP. Most clinical guidelines recommend providing advice and educational strategies for people experiencing LBP, including re-engagement in physical activity and exercise, and supporting self-management of LBP symptoms to improve function [4]. While other interventions may be needed to manage symptoms in people with acute or chronic LBP, such as medicines, their judicious use should not be the only focus of care. More invasive interventions such as spinal injections may be considered when non-invasive treatments have not provided a sufficient benefit, and a clear clinical indication supports their use. With many different options available, information on the cost-effectiveness of interventions to manage LBP is critical to those making funding decisions. A 2011 systematic review (26 studies) investigated the cost-effectiveness of interventions recommended in the 2007 American College of Physicians and American Pain Society joint LBP clinical guidelines [5, 6]. The authors concluded that the evidence supported the cost-effectiveness of interdisciplinary rehabilitation, exercise, acupuncture, spinal manipulation and cognitive behavioural therapy. The studies included in the review showed substantial heterogeneity in their comparison interventions, limiting the transferability of their findings to policy and practice. In 2018, Miyamoto, in a systematic review (16 studies) of the cost-effectiveness of exercise for LBP, concluded that it may be cost-effective when compared to usual care (e.g., first contact management) [7]. In 2018, Salathé, in a systematic review of the effectiveness of multidisciplinary biopsychosocial rehabilitation (MBR; 13 studies), found some evidence to support its cost-effectiveness [8]. In 2017, Andronis, in a systematic review (33 studies), found that combined physical and psychological treatments, information and education interventions, and manual therapies could be cost-effective, but that there was inconsistent evidence on the cost-effectiveness of physical exercise programmes [9]. Since these reviews were published, there have been new recommendations from high-quality guidelines for the management of LBP, informed by new evidence from robust clinical trials [10–12]. No review has evaluated the cost-effectiveness of all interventions recommended in contemporary clinical practice guidelines, compared to usual care. Summarising and evaluating the most updated evidence of the cost-effectiveness of interventions recommended for LBP care in clinical practice guidelines can support policymakers and health services in decisions about funding of interventions and their availability. This is particularly relevant in the context of determining essential care packages for Universal Health Coverage. We have conducted a systematic review to critically appraise and summarise the evidence on the cost-effectiveness and costs of interventions recommended (in favour) in recent guidelines to manage LBP, compared to usual care.
Methods
The protocol for this systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P and PRISMA) and Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. The review was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (https://www.crd.york.ac.uk; CRD42024510270). This study is reported as per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (S1 Checklist).
Patient and public involvement
Consumer representatives were not involved in the design not the conduct of this systematic review. Consumer representatives and those with lived experience will be involved in the dissemination of the study findings, according to the Consumer Engagement and Involvement Framework of The George Institute for Global Health, Australia.
Search strategy
We searched electronic databases from inception to the 9th February 2026 using a search strategy developed following published Cochrane reviews on back pain and economic analyses and librarian input. We searched MEDLINE (OvidSP), EMBASE (OvidSP), PsycINFO (OvidSP), Cochrane Central Register of Controlled Trials (CENTRAL) (OvidSP), CINAHL Complete (EBSCOhost), EconLit with full text (EBSCO), The Tufts Cost-effectiveness Analysis Registry (CEA), NHS Economic Evaluation Database (OvidSP), Health Technology Assessment (HTA) (OvidSP), and International Pharmaceutical Abstracts (OvidSP) with no restrictions. The search strategy is detailed in S1 File and was adapted for each database. We also conducted a manual search of relevant systematic reviews and email communication with content experts to identify missing literature.
Eligibility
Types of studies.
We included cost-effectiveness evaluations based on randomised controlled trials or modelling studies of eligible interventions for the management of LBP. We considered model-based economic evaluations that relied on inputs from randomised trials (i.e., micro-simulation modelling) or external information that provides inputs from multiple cost sources. We excluded Phase I and II clinical trials, opinion pieces, editorials, abstracts, case series reports and reviews.
Population.
We included studies with adult (≥18 years) participants with non-specific LBP (where the experience of pain is not reliably attributed to nociceptive input from a specific structure) with or without leg pain. We excluded studies on participants with radiculopathy (or sciatica) only, or where the primary area of pain was not the lower back (i.e., between the 12th rib and the gluteal folds). We also excluded studies that enrolled participants with LBP attributed to distinct pathologies, such as cancer, osteoporosis, infection, fracture, trauma, and autoimmune inflammatory diseases, as well as studies focussing on participants that had undergone spinal surgery within the last 12 months, those who were pregnant or did not present data separately for LBP if mixed populations were sampled (e.g., lumbar and cervical pain). We considered the experience of LBP as acute (less than 6 weeks), subacute (6–12 weeks) or chronic (greater than 12 weeks).
Intervention.
We included studies that assessed LBP interventions as recommended by at least one of the following guidelines: World Health Organization [12], National Institute for Health and Care Excellence [10], and North American Spine Society [11]. We only included studies assessing interventions where the direction of the recommendation was in favour of using/offering the intervention in at least one of these guidelines, regardless of the strength of the recommendation (e.g., strong or conditional), certainty of the evidence, or dose/duration (S2 File). We did not include guidelines that were greater than five years old at the time of protocol development [13], focussed on one class of interventions to manage LBP (e.g., physical therapies alone) [14], or on one discrete population (e.g., veterans). We did not include clinical care standards designed for quality improvement in key areas (e.g.[15],). We did not include studies that reported the use of health services, such as studies of claim databases where no intervention was implemented.
Comparator.
In the current report, we have only included studies using sham/placebo, usual care (i.e., first contact care), or no treatment controls. This was decided as the focus of the current review is on the cost-utility of guideline-recommended interventions that may be commissioned, rather than the comparative cost-effectiveness of these interventions.
Outcomes
Our primary outcome was the incremental cost per quality-adjusted life year (QALY) gained by the intervention group compared with the comparator, as reported by studies of relevant, included interventions. We also report willingness to pay (WTP) according to the thresholds as reported in the original studies, and any incremental net monetary benefit analyses. Secondary outcomes included direct costs (total costs, intervention costs, costs with health service use, community services costs, and out-of-pocket costs) and indirect costs (e.g., lost wages, lost productivity, and absenteeism). To evaluate the specific economic burden on workers, we defined direct costs as the immediate healthcare resources consumed by the intervention, while indirect costs were the broader societal productivity losses, explicitly capturing work absenteeism, presenteeism, and lost wages as extracted from the primary trial data.
Screening
Two review authors from a panel (SM, MI, ZH, MU, ZZ, MLF) independently screened and identified titles and abstracts to determine eligibility. We excluded duplicate studies. Two reviewers independently appraised the full texts of potentially eligible studies to determine inclusion. Disagreements were resolved by discussion first. If needed a third independent reviewer (MLF, MU) arbitrated. For articles written in languages that the authors could not read, the authors sought colleagues to assist with reading the article or used Google Translate to screen for eligibility.
Data extraction and management
Two review authors from a panel (SM, MU, MI, ZH, ZZ, PHF, MLF) independently extracted data using standardised, piloted data extraction forms in Covidence. Disagreements were resolved by discussion first. If needed, a third independent reviewer (MLF, MU) arbitrated. The reviewers did not assess any of their own studies. We extracted the following information when available on bibliometric data (authors, title, year of publication, language, country, funding sources); study characteristics (setting, sample size, study design, e.g., randomised trial, modelling study, sampling details); participants (age, sex, race/ethnicity, diagnosis/LBP classification, symptom duration); interventions and controls (type, dose, duration, mode of delivery); outcome data (type of economic evaluation, incremental cost-effectiveness measures of base-case analyses, type of costs evaluated and details for secondary outcomes, perspective (e.g., societal, health system, etc.), time horizon, currency, price year, discount rates, and tariffs).
Quality assessment
Two reviewers from a panel (SM, MLF, ZZ, HM) independently assessed the methodological quality of eligible studies using the 19-item Consensus on Health Economic Criteria (CHEC) checklist for randomised trials [16], and the Philips checklist for modelling studies (S3 File) [17]. Disagreements were arbitrated by a third reviewer (PHF) if consensus was not reached.
Strategy for data synthesis and analysis
The flow of studies is summarised in a study flow diagram, following the PRISMA statement [18]. We reported study and participant characteristics descriptively and dichotomous variables as proportions, n/N (%). We reported continuous variables using point and variability estimates (e.g., means and standard deviations or medians and interquartile ranges). We tabulated and qualitatively summarised the primary outcomes (cost per QALY) of cost-effectiveness evaluations. Where available, we also presented the average cost difference between interventions, QALY (and 95% confidence intervals [CI]), and WTP for one QALY. We presented costs in the original study currency as well as in 2024 GBP (Great British Pounds (£)). We first inflated cost estimates reported in each study to 2024 price levels using country-specific Consumer Price Index (CPI) data obtained from the Organisation for Economic Co-operation and Development (https://www.oecd.org/en.html), relative to the original study year. We then converted costs expressed in 2024 local currency to 2024 British pounds (£) by dividing by the corresponding 2024 country-specific Purchasing Power Parity (PPP) for gross domestic product (GDP). We set our notional WTP threshold at £20,000 Great British Pounds per QALY, as it corresponds to the current NICE recommended threshold. This was done to maintain contextual precision across different international healthcare systems. We standardised all cost and utility values by extracting the primary data, adjusting for inflation using the localised CPI relative to the specific year of each study’s execution, and converting them into a baseline currency to ensure accurate and meaningful cross-contextual comparisons.
We present the results separately for different perspectives: healthcare, societal, payer or employer. We classified the income status of countries using the 2025 World Bank income classification into low-income, middle-income (upper- or lower-middle), or high-income [19]. The heterogeneity of study populations, interventions, perspectives, and the health and social care systems in which the work was done made any data pooling inappropriate. Moreover, we deemed pooling inappropriate due to the absence of measures of variance for economic outcomes. We assessed between-study heterogeneity qualitatively across structural, clinical, and methodological domains prior to synthesis, including (1) disparate economic perspectives; (2) highly variable time horizons (≤12 months to lifetime models); and (3) heterogeneous geographic cost structures. We present a narrative synthesis to preserve the contextual validity of the findings.
Likewise, while the study protocol initially planned for a Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment of the primary outcomes, during data synthesis we determined that the currently available GRADE frameworks [20] would be methodologically unsuited for evaluating synthesised economic evidence and therefore not included in this review. Generative AI was not used in this study.
Results
The initial search retrieved 9,285 records, of which 20 papers reporting on 24 studies and providing the cost-effectiveness of 55 comparisons with usual care (e.g., general practitioner-delivered first contact care, usual physiotherapy care) were included [21–40]. Fig 1 presents a flow of studies. Studies were published between 2005 [34] and 2026 [40] and were from 9 high-income countries, most frequently from the UK (n = 7 studies, 37%, Table 1). Most studies (n = 17) were cost-effectiveness analyses of randomised trial data. There were 3 model-based studies [32, 35, 36]. We identified one study [35] that used original data from 17 trials to estimate cost-utility for different interventions against usual care controls for a standardised back pain population. Of these studies, 10 met our inclusion criteria, four of which [21, 24, 29, 34] had already been identified and reported in our review. The remaining six provided new data on 10 comparisons and were included in our economic analysis [41–46].
Total number of participants included in the cost-effectiveness analyses was 14,884 with a mean sample size per comparison of 266 [range: 134 [30] to 2,982 [32] (Table 1)]. Participants’ mean age ranged from 45.5 [26] to 74.1 years [40]. Sex or gender was reported in 16 studies. Among those reporting this information, 5,954/10,309 female participants (58%) were included in the cost-effectiveness analyses. Approximately half of the studies were of people only experiencing chronic symptoms (n = 10 studies; 55%), with eight of the remaining studies including a population of mixed LBP duration (Table 1). One study only included participants with acute symptoms [39], while the remaining study did not report the symptom duration [32]. We detail the characteristics of the included studies and their participants in Table 1.
Intervention characteristics
All studies were of non-pharmacological, non-surgical interventions, with most assessing the cost-effectiveness of acupuncture (5 studies, 16 comparisons) [35–37, 39, 40], or cognitive and psychological therapies (6 studies, 7 comparisons) [23, 24, 27, 29, 30, 38]. Included studies also evaluated the cost-effectiveness of single-modality interventions such as exercises [34], Yoga [21], massage [26, 41, 45], spinal manipulation [32, 34], and multimodal interventions, including multidisciplinary care [25, 43], combined exercise and spinal manipulation [34], exercise and cognitive therapy [38], education and advice [22, 28, 31] or lifestyle-based intervention [33], compared to usual care. In the included studies, usual care was broadly defined as first-contact care and mostly comprised of education (e.g., Back School booklet), limited pharmacotherapy, advice to stay active and when needed, or referral to a physiotherapist (Table 2). Suman and colleagues [31] provided participants in the usual care, a digital patient information letter, and Williams and colleagues [33] defined usual care as normal care delivered while on the waitlist to receive surgery. Fig 2 provides a summary of the types, frequency and guideline endorsement of included interventions.
Economic evaluation characteristics
All studies were from high-income countries. Eighteen comparisons from 13 studies [21–24, 26, 28–30, 33, 34, 38–40] considered a healthcare system perspective, 21 comparisons (10 included studies [21, 22, 24, 27, 28, 30, 31, 33, 35, 37]) considered a societal perspective, and 14 comparisons (4 studies [22, 25, 35, 40]) a payer perspective. The probability of being cost-effective at a WTP threshold was reported in 21 comparisons and ranged from 50.0% to 99.6% probability of cost-effectiveness over usual care (Table 3).
Methodology quality
Economic evaluation studies were in general of high methodological quality. Eight of the 19 CHEC checklist criteria were met by all trial-based economic evaluations (e.g., clear description of the study population, research question, appropriateness of study design, and time horizon). The least comprehensively reported study assessed with the CHEC checklist was by Johnson and colleagues [38] meeting 13 of the 19 checklist criteria (Table 4). Using the Philips checklist for the three modelling studies, the least comprehensively reported study was by Herman and colleagues (2020) [35] which met only 2 of the 57 item criteria. The most comprehensively reported study was by Kim and colleagues (2010) [36] which met the criteria for 11 of the 57 items (see Table 5).
Primary outcome
We report the main results based on the primary outcome, incremental cost-effectiveness ratio (ICER) expressed as cost/QALY in Table 3, sorted by perspective and ranked in order of cost-effectiveness. From the within-trial economic analyses, 6 single-modality interventions (yoga, acupuncture, cognitive behavioural therapy, self-management support, fear reduction education and mindfulness stress reduction) and 2 multimodal interventions (advice plus graded activity at the workplace, healthy lifestyle (diet plus physical activity)) were more effective and less costly than usual care; i.e., intervention dominated control from one or more perspectives (Table 3) [21–24, 27, 30, 31, 33]. In one modelling study, osteopathy was also found to dominate usual care [32]. In only one comparison, a trial of massage therapy, did the control intervention dominate the intervention.
From a healthcare perspective in 14/18 comparisons (e.g., exercise plus cognitive therapy, exercise alone, spinal manipulation) the intervention was cost-effective at our notional WTP threshold of £20,000. Of the nine comparisons reporting the probability of cost-effectiveness, levels of certainty ranged from 27% at £14,697 for standard acupuncture to 98% at £18,181 app-based self-management support [28, 40].
From a societal perspective in 15/19 comparisons (e.g., therapeutic and structural massage, physiotherapy) the intervention was cost effective at our notional WTP threshold of £20,000. The probability of an intervention being cost-effective was reported in nine comparisons and levels of certainty ranged from ~50% at £18,181 for app-based self-management to 96% at £39,384 for a healthy lifestyle intervention [28, 33].
From a payer perspective, in 11/14 trial-based comparisons (e.g., physiotherapy, massage, multidisciplinary intervention, spinal manipulation), the intervention appears to be cost-effective at our notional WTP threshold of £20,000. Of the two comparisons for which the probability of an intervention being cost-effective was reported, levels of certainty ranged from 64% at £17,686 for MBR to ~85%% at £24,006 for GP training in fear reduction [22, 25].
Both studies modelling cost-effectiveness of osteopathy and acupuncture also found a cost per QALY below our notional WTP threshold of £20,000 from a payer perspective [32, 36]. Only one study reported the net monetary benefit of the evaluated intervention. Darlow and colleagues [22] showed that adding fear reduction education to general practice care of LBP yields NZ$542 (95% CI −678, 1,762) (£281 [95%CI −411, 1,067]) more in value than it costs compared with general practitioner (GP) care alone, from a healthcare perspective, NZ$609 (95% CI −1,385, 2,603) (£315 [95%CI −839, 1,577]) from a societal perspective and NZ$-695 (95%CI −496, 1,885) (£ −360 [95%CI −301, 1,142]) from a payer perspective at a WTP threshold of NZ$ = 55,615 (£32,740).
Secondary outcomes
We summarise the economic costs related to secondary outcomes of direct and indirect costs in S5 File. All studies reported total costs, such as interventional costs of healthcare. Nine studies reported indirect costs (64%) [21–24, 27, 28, 30, 31, 33, 47–76]. Lost productivity and absenteeism were the most common individual indirect costs reported (detailed in S4 File—Table).
Discussion
For those interventions recommended in selected current LBP guidelines for which health economic analyses are available, our findings show a consistent pattern that many non-pharmacologic and non-surgical single-modality and multimodal, clinician-delivered interventions represent good value for money from whichever perspective has been assessed. Compared to usual care, yoga, acupuncture, cognitive interventions, fear and stress reduction therapies, and self-management support are potentially cost-saving, single-modality treatments shown to be more effective and reduce overall costs (e.g., £2,671 reduction of societal costs for cognitive functional therapy; £396 reduction of healthcare costs for acupuncture). Moreover, multimodal, combined therapies, such as healthy lifestyle promotion (diet plus physical activity), and advice plus graded activity, were shown to be more effective and to incur fewer costs than usual medical care (i.e., £7,315 reduction in societal costs for workplace advice and graded activity, and £361 reduction for diet plus exercise). Other combined therapies, including exercise and spinal manipulation, exercise and cognitive therapy, and multidisciplinary rehabilitation are also cost-effective, compared to usual care, at least from societal and payer perspectives. Massage therapy and acupuncture were commonly evaluated across included studies, however, with inconsistent results, suggesting their cost-effectiveness varies substantially with context, perspective and mode of delivery. Given the high level of heterogeneity across studies in terms of perspectives, comparators, methodological quality of original randomised trial data and country settings, these results should be interpreted with caution.
Previous systematic reviews on the cost-effectiveness of treatments for LBP have been specific to individual therapies [7, 8, 77], with no comprehensive review of internationally recommended, guideline-concordant recommendations for managing acute and chronic LBP. Since the last review was published in 2019, 9 new economic evaluations meeting our eligibility criteria have been published and included in our main results. Our review, however, has identified that interventions that aim at reducing fear and stress related to LBP, as well as clinician-delivered mind-body therapies, such as yoga, acupuncture, and cognitive behavioural therapy, can be potentially cost-saving, as they are both more effective and less costly than usual medical care. These interventions are still far from being routinely implemented or commissioned in most countries. Future efforts should focus on elucidating and addressing the factors contributing to this gap and to inform strategies aimed at reducing it.
The evidence generated in this systematic review highlights that multiple guideline-recommended treatments for LBP offer good value for money, over usual care, with many offering potential cost-savings to society, and healthcare system. Efforts must now focus on implementing these interventions at scale to ensure their benefits are fully realised. Our findings also highlight that cost-related recommendations for managing LBP in low- to middle-income countries remain limited, as generalisations from high-income countries, although appropriate in some components, are unlikely to be relevant. Healthcare resources can be limited in some settings, contexts and countries, and hence, policymakers and clinicians should tailor and optimise treatment approaches with dynamic, local considerations, including options to reduce inequities in access to care, e.g., through harnessing digitally-enabled service models.
Undertaking a thorough, unrestricted search for studies of guideline-recommended interventions to manage LBP compared to usual care provides the current context and landscape of the topic. The internationally recognised guidelines used in this review will likely be known and used by clinicians. Although we were unable to conduct a meta-analysis due to the heterogeneity of included study designs and jurisdictions, this systematic review is the first to our knowledge to summarise direct and indirect costs of guideline-recommended interventions used to manage LBP. We observed heterogeneity in the data, including how cost-effectiveness was measured and a lack of standardisation in reporting costs. Studies reporting direct costs included intervention or total costs but infrequently reported community services costs, out-of-pocket costs, and indirect costs. Moreover, costs are context-specific and may have limited generalisability beyond the healthcare system in which they were collected and reported. Furthermore, the current evidence regarding specific LBP populations (e.g., sciatica) was not included in the current report. Standard GRADE criteria (e.g., blinding, directness) do not adequately capture the core drivers of economic uncertainty, such as model structure, parameter inputs, and time-horizon assumptions. Consequently, to ensure a technically rigorous evaluation, we deviated from the protocol by omitting GRADE and instead utilising established, specific health economic appraisal tools (including the CHEC checklist) to assess evidence quality and methodological certainty. Pre-specified subgroup stratifications, as well as distinct sensitivity analyses (e.g., restricting cohorts to chronic LBP), could not be executed due to an inadequate volume of split-sample primary data. Finally, to ensure a consistent baseline benchmark, this review restricted eligible comparators to usual care, sham/placebo, or no treatment. While multi-arm active economic evaluations offer direct comparative utility within localised contexts, their inclusion in a broad global synthesis introduces further heterogeneity and limits the relevance of the results to policy and service model considerations, particularly in the context of financing and commissioning decisions and decisions about which interventions may be appropriately considered in Universal Health Coverage essential packages. Restricting the comparator to a standard baseline allows for a clearer evaluation of the absolute incremental economic value of guideline-recommended interventions relative to routine clinical practice or no care.
The high burden, costs and disability that LBP places on society, impacting millions worldwide, make the management of LBP a global priority. The lack of evidence related to cost-effectiveness in managing LBP from the perspective of low- to middle-income countries highlights a clear opportunity for future, high-quality research [78]. While standardising the cost-effectiveness measures (e.g., ICER) may assist consistency in future studies, extending the reporting of costs beyond intervention and total costs (e.g., lost productivity and community costs) would enable more accurate measures of burden. Finally, we have identified the urgent need for cost-effectiveness data on pharmacological and surgical interventions for LBP, given how commonly these are accessed and funded globally.
Supporting information
S1 Checklist. PRISMA checklist.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv. 2020, September 14. https://doi.org/10.31222/osf.io/v7gm2. For more information, visit: https://www.prisma-statement.org.
https://doi.org/10.1371/journal.pmed.1005273.s001
(DOCX)
S2 File. Eligible interventions to manage low back pain.
https://doi.org/10.1371/journal.pmed.1005273.s003
(DOCX)
S4 File. Direct and indirect costs in included studies.
https://doi.org/10.1371/journal.pmed.1005273.s005
(DOCX)
S5 File. Studies excluded from this report and main reason for exclusion.
https://doi.org/10.1371/journal.pmed.1005273.s006
(DOCX)
References
- 1. Ferreira ML, de Luca K, Haile LM, et al. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(6):e316–29.
- 2. Fatoye F, Gebrye T, Ryan CG, Useh U, Mbada C. Global and regional estimates of clinical and economic burden of low back pain in high-income countries: a systematic review and meta-analysis. Front Public Health. 2023;11:1098100. pmid:37383269
- 3.
Australian Institute of Health and Welfare AIHW. Back problems. Canberra: Australian Institute of Health and Welfare. 2023.
- 4. McKenzie BJ, Haas R, Ferreira GE, Gorelik A, Cyril S, Han JX, et al. Agreement between high-quality clinical practice guidelines in their treatment recommendations for low back pain: a systematic review. Spine J. 2025;25(12):2587–604. pmid:40639620
- 5. Lin C-WC, Haas M, Maher CG, Machado LAC, van Tulder MW. Cost-effectiveness of guideline-endorsed treatments for low back pain: a systematic review. Eur Spine J. 2011;20(7):1024–38. pmid:21229367
- 6. Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478–91. pmid:17909209
- 7. Miyamoto GC, Lin C-WC, Cabral CMN, van Dongen JM, van Tulder MW. Cost-effectiveness of exercise therapy in the treatment of non-specific neck pain and low back pain: a systematic review with meta-analysis. Br J Sports Med. 2019;53(3):172–81. pmid:29678893
- 8. Salathé CR, Melloh M, Crawford R, Scherrer S, Boos N, Elfering A. Treatment efficacy, clinical utility, and cost-effectiveness of multidisciplinary biopsychosocial rehabilitation treatments for persistent low back pain: a systematic review. Global Spine J. 2018;8(8):872–86. pmid:30560041
- 9. Andronis L, Kinghorn P, Qiao S, Whitehurst DGT, Durrell S, McLeod H. Cost-effectiveness of non-invasive and non-pharmacological interventions for low back pain: a systematic literature review. Appl Health Econ Health Policy. 2017;15(2):173–201. pmid:27550240
- 10.
National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: Assessment and management. 2020.
- 11.
North American Spine Society (NASS). Evidence-based clinical guidelines for multidisciplinary spine care: diagnosis & treatment of low back pain. Illinois: North American Spine Society (NASS); 2020.
- 12.
World Health Organization WHO. WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings. Geneva: World Health Organization; 2023.
- 13. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians, Denberg TD, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–30. pmid:28192789
- 14.
Koninklijk Nederlands Genootschap voor Fysiotherapie KNGF. KNGF Guideline on low back pain and lumbosacral radicular syndrome. Amersfoort/Utrecht: KNGF/VvOCM; 2021.
- 15.
Australian Commission on Safety and Quality in Health Care. Low back pain clinical care standard. 2022.
- 16. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–5. pmid:15921065
- 17. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355–71. pmid:16605282
- 18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. pmid:33782057
- 19.
The World Bank. World Bank country classification by income. The World Bank; 2025.
- 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. pmid:21195583
- 21. Chuang L-H, Soares MO, Tilbrook H, Cox H, Hewitt CE, Aplin J, et al. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation. Spine (Phila Pa 1976). 2012;37(18):1593–601. pmid:22433499
- 22. Darlow B, Stanley J, Dean S, Abbott JH, Garrett S, Wilson R, et al. The Fear Reduction Exercised Early (FREE) approach to management of low back pain in general practice: a pragmatic cluster-randomised controlled trial. PLoS Med. 2019;16(9):e1002897. pmid:31498799
- 23. Geraghty AWA, Becque T, Roberts LC, Hill JC, Foster NE, Yardley L, et al. Supporting self-management of low back pain with an internet intervention with and without telephone support in primary care (SupportBack 2): a randomised controlled trial of clinical and cost-effectiveness. Lancet Rheumatol. 2024;6(7):e424–37. pmid:38824934
- 24. Herman PM, Anderson ML, Sherman KJ, Balderson BH, Turner JA, Cherkin DC. Cost-effectiveness of mindfulness-based stress reduction versus cognitive behavioral therapy or usual care among adults with chronic low back pain. Spine (Phila Pa 1976). 2017;42(20):1511–20. pmid:28742756
- 25. Hochheim M, Ramm P, Wunderlich M, Amelung V. Cost-effectiveness analysis of a chronic back pain multidisciplinary biopsychosocial rehabilitation (MBR) compared to standard care for privately insured in Germany. BMC Health Serv Res. 2021;21(1):1362. pmid:34952585
- 26. Hollinghurst S, Sharp D, Ballard K, Barnett J, Beattie A, Evans M, et al. Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. BMJ. 2008;337:a2656. pmid:19074232
- 27. Kent P, Haines T, O’Sullivan P, Smith A, Campbell A, Schutze R, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. Lancet. 2023;401(10391):1866–77. pmid:37146623
- 28. Kongstad LP, Øverås CK, Skovsgaard CV, Sandal LF, Hartvigsen J, Søgaard K, et al. Cost-effectiveness analysis of app-delivered self-management support (selfBACK) in addition to usual care for people with low back pain in Denmark. BMJ Open. 2024;14(9):e086800. pmid:39242164
- 29. Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. A multicentred randomised controlled trial of a primary care-based cognitive behavioural programme for low back pain. The Back Skills Training (BeST) trial. Health Technol Assess. 2010;14(41):1–253, iii–iv. pmid:20807469
- 30. Lambeek LC, Bosmans JE, Van Royen BJ, Van Tulder MW, Van Mechelen W, Anema JR. Effect of integrated care for sick listed patients with chronic low back pain: economic evaluation alongside a randomised controlled trial. BMJ. 2010;341:c6414. pmid:21118874
- 31. Suman A, Schaafsma FG, van Dongen JM, Elders PJM, Buchbinder R, van Tulder MW, et al. Effectiveness and cost-utility of a multifaceted eHealth strategy to improve back pain beliefs of patients with non-specific low back pain: a cluster randomised trial. BMJ Open. 2019;9(12):e030879. pmid:31811006
- 32. Verhaeghe N, Schepers J, van Dun P, Annemans L. Osteopathic care for low back pain and neck pain: a cost-utility analysis. Complement Ther Med. 2018;40:207–13. pmid:30219451
- 33. Williams A, van Dongen JM, Kamper SJ, O’Brien KM, Wolfenden L, Yoong SL, et al. Economic evaluation of a healthy lifestyle intervention for chronic low back pain: A randomized controlled trial. Eur J Pain. 2019;23(3):621–34. pmid:30379386
- 34. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ. 2004;329(7479):1381. pmid:15556954
- 35. Herman PM, McBain RK, Broten N, Coulter ID. Update of Markov model on the cost-effectiveness of nonpharmacologic interventions for chronic low back pain compared to usual care. Spine (Phila Pa 1976). 2020;45(19):1383–5. pmid:32516169
- 36. Kim N, Yang B, Lee T, Kwon S. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis. BMC Complement Altern Med. 2010;10:74. pmid:21106108
- 37. Ratcliffe J, Thomas KJ, MacPherson H, Brazier J. A randomised controlled trial of acupuncture care for persistent low back pain: cost effectiveness analysis. BMJ. 2006;333(7569):626. pmid:16980315
- 38. Johnson RE, Jones GT, Wiles NJ, Chaddock C, Potter RG, Roberts C, et al. Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. Spine (Phila Pa 1976). 2007;32(15):1578–85. pmid:17621203
- 39. Skonnord T, Fetveit A, Skjeie H, Brekke M, Grotle M, Klovning A, et al. Cost-effectiveness analysis of acupuncture compared with usual care for acute non-specific low back pain: secondary analysis of a randomised controlled trial. Acupunct Med. 2022;40(2):123–32. pmid:34847780
- 40. Herman PM, Mann S, DeBar LL, Avins AL, Justice M, Nielsen A, et al. Cost-effectiveness of acupuncture needling for older adults with chronic low back pain. Spine (Phila Pa 1976). 2026;51(3):E65–75. pmid:41493335
- 41. Cherkin DC, Sherman KJ, Kahn J, Wellman R, Cook AJ, Johnson E, et al. A comparison of the effects of 2 types of massage and usual care on chronic low back pain: a randomized, controlled trial. Ann Intern Med. 2011;155(1):1–9. pmid:21727288
- 42. Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, et al. A randomized trial of medical care with and without physical therapy and chiropractic care with and without physical modalities for patients with low back pain: 6-month follow-up outcomes from the UCLA low back pain study. Spine (Phila Pa 1976). 2002;27(20):2193–204. pmid:12394892
- 43. Von Korff M, Balderson BHK, Saunders K, Miglioretti DL, Lin EHB, Berry S, et al. A trial of an activating intervention for chronic back pain in primary care and physical therapy settings. Pain. 2005;113(3):323–30. pmid:15661440
- 44. Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, Barlow WE, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med. 2009;169(9):858–66. pmid:19433697
- 45. Cherkin DC, Eisenberg D, Sherman KJ, Barlow W, Kaptchuk TJ, Street J, et al. Randomized trial comparing traditional Chinese medical acupuncture, therapeutic massage, and self-care education for chronic low back pain. Arch Intern Med. 2001;161(8):1081–8. pmid:11322842
- 46. Haake M, Müller H-H, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med. 2007;167(17):1892–8. pmid:17893311
- 47. Aboagye E, Karlsson ML, Hagberg J, Jensen I. Cost-effectiveness of early interventions for non-specific low back pain: a randomized controlled study investigating medical yoga, exercise therapy and self-care advice. J Rehabil Med. 2015;47(2):167–73. pmid:25403347
- 48. Ademi Z, Gloy V, Glinz D, Raatz H, Van Stiphout J, Bucher HC, et al. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Med Wkly. 2016;146:w14382. pmid:27922167
- 49. Bachmann S, Wieser S, Oesch P, Schmidhauser S, Knüsel O, Kool J. Three-year cost analysis of function-centred versus pain-centred inpatient rehabilitation in patients with chronic non-specific low back pain. J Rehabil Med. 2009;41(11):919–23. pmid:19841844
- 50. Brown KC, Sirles AT, Hilyer JC, Thomas MJ. Cost-effectiveness of a back school intervention for municipal employees. Spine (Phila Pa 1976). 1992;17(10):1224–8. pmid:1440013
- 51. Çakmak Başer Ö, Ay S, Evcik D. Cost-effectiveness analysis of chronic mechanical back pain treatment modalities. Turk J Phys Med Rehabil. 2020;66(4):413–22. pmid:33364561
- 52. Goossens MEJB, de Kinderen RJA, Leeuw M, de Jong JR, Ruijgrok J, Evers SMAA, et al. Is exposure in vivo cost-effective for chronic low back pain? A trial-based economic evaluation. BMC Health Serv Res. 2015;15:549. pmid:26651828
- 53. Haines T, Bowles K-A. Cost-effectiveness of using a motion-sensor biofeedback treatment approach for the management of sub-acute or chronic low back pain: economic evaluation alongside a randomised trial. BMC Musculoskelet Disord. 2017;18(1):18. pmid:28095832
- 54. Hemmilä HM. Quality of life and cost of care of back pain patients in Finnish general practice. Spine (Phila Pa 1976). 2002;27(6):647–53. pmid:11884913
- 55. Henchoz Y, Pinget C, Wasserfallen J-B, Paillex R, de Goumoëns P, Norberg M, et al. Cost-utility analysis of a three-month exercise programme vs usual care following multidisciplinary rehabilitation for chronic low back pain. J Rehabil Med. 2010;42(9):846–52. pmid:20878045
- 56. Hlobil H, Uegaki K, Staal JB, de Bruyne MC, Smid T, van Mechelen W. Substantial sick-leave costs savings due to a graded activity intervention for workers with non-specific sub-acute low back pain. Eur Spine J. 2007;16(7):919–24. pmid:17186282
- 57. Koppenaal T, van Dongen JM, Kloek CJ, Arensman RM, Veenhof C, Pisters MF, et al. Effectiveness and cost-effectiveness of a stratified blended physiotherapy intervention compared with face-to-face physiotherapy in patients with nonspecific low back pain: cluster randomized controlled trial. J Med Internet Res. 2023;25:e43034. pmid:37999947
- 58. Lee C-C, Chen C-J, Chou C-C, Wang H-Y, Chung W-Y, Peng G-S, et al. Lumbar dorsal root ganglion block as a prognostic tool before pulsed radiofrequency: a randomized, prospective, and comparative study on cost-effectiveness. World Neurosurg. 2018;112:e157–64. pmid:29317362
- 59. Luijsterburg PAJ, Lamers LM, Verhagen AP, Ostelo RWJG, van den Hoogen HJMM, Peul WC, et al. Cost-effectiveness of physical therapy and general practitioner care for sciatica. Spine (Phila Pa 1976). 2007;32(18):1942–8. pmid:17700438
- 60. Miyamoto GC, Franco KFM, van Dongen JM, Franco YRDS, de Oliveira NTB, Amaral DDV, et al. Different doses of Pilates-based exercise therapy for chronic low back pain: a randomised controlled trial with economic evaluation. Br J Sports Med. 2018;52(13):859–68. pmid:29525763
- 61. Moffett JK, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. BMJ. 1999;319(7205):279–83. pmid:10426734
- 62. Niemistö L, Rissanen P, Sarna S, Lahtinen-Suopanki T, Lindgren K-A, Hurri H. Cost-effectiveness of combined manipulation, stabilizing exercises, and physician consultation compared to physician consultation alone for chronic low back pain: a prospective randomized trial with 2-year follow-up. Spine (Phila Pa 1976). 2005;30(10):1109–15. pmid:15897822
- 63. Pennington Z, Swanson MA, Lubelski D, Mehta V, Alvin MD, Fuhrman H, et al. Comparing the short-term cost-effectiveness of epidural steroid injections and medical management alone for discogenic lumbar radiculopathy. Clin Neurol Neurosurg. 2020;191:105675. pmid:31954364
- 64. Rhon DI, Miller RB, Fritz JM. Effectiveness and downstream healthcare utilization for patients that received early physical therapy versus usual care for low back pain: a randomized clinical trial. Spine (Phila Pa 1976). 2018;43(19):1313–21. pmid:29489568
- 65. Rivero-Arias O, Gray A, Frost H, Lamb SE, Stewart-Brown S. Cost-utility analysis of physiotherapy treatment compared with physiotherapy advice in low back pain. Spine (Phila Pa 1976). 2006;31(12):1381–7. pmid:16721304
- 66. Rogerson MD, Gatchel RJ, Bierner SM. A cost utility analysis of interdisciplinary early intervention versus treatment as usual for high-risk acute low back pain patients. Pain Pract. 2010;10(5):382–95. pmid:20384967
- 67. Schweikert B, Jacobi E, Seitz R, Cziske R, Ehlert A, Knab J, et al. Effectiveness and cost-effectiveness of adding a cognitive behavioral treatment to the rehabilitation of chronic low back pain. J Rheumatol. 2006;33(12):2519–26. pmid:17143986
- 68. Skouen JS, Grasdal AL, Haldorsen EMH, Ursin H. Relative cost-effectiveness of extensive and light multidisciplinary treatment programs versus treatment as usual for patients with chronic low back pain on long-term sick leave: randomized controlled study. Spine (Phila Pa 1976). 2002;27(9):901–9; discussion 909-10. pmid:11979157
- 69. Smeets RJ, Severens JL, Beelen S, Vlaeyen JW, Knottnerus JA. More is not always better: cost-effectiveness analysis of combined, single behavioral and single physical rehabilitation programs for chronic low back pain. Eur J Pain. 2009;13(1):71–81. pmid:18434221
- 70. Steenstra IA, Anema JR, van Tulder MW, Bongers PM, de Vet HCW, van Mechelen W. Economic evaluation of a multi-stage return to work program for workers on sick-leave due to low back pain. J Occup Rehabil. 2006;16(4):557–78. pmid:17086503
- 71. Teng M, Zhou HJ, Lin L, Lim PH, Yeo D, Goh S, et al. Cost-effectiveness of hydrotherapy versus land-based therapy in patients with musculoskeletal disorders in Singapore. J Public Health (Oxf). 2019;41(2):391–8. pmid:29534234
- 72. Torstensen TA, Ljunggren AE, Meen HD, Odland E, Mowinckel P, Geijerstam S. Efficiency and costs of medical exercise therapy, conventional physiotherapy, and self-exercise in patients with chronic low back pain. A pragmatic, randomized, single-blinded, controlled trial with 1-year follow-up. Spine (Phila Pa 1976). 1998;23(23):2616–24. pmid:9854761
- 73. van der Roer N, van Tulder M, van Mechelen W, de Vet H. Economic evaluation of an intensive group training protocol compared with usual care physiotherapy in patients with chronic low back pain. Spine (Phila Pa 1976). 2008;33(4):445–51. pmid:18277878
- 74. Vavrek DA, Sharma R, Haas M. Cost analysis related to dose-response of spinal manipulative therapy for chronic low back pain: outcomes from a randomized controlled trial. J Manipulative Physiol Ther. 2014;37(5):300–11. pmid:24928639
- 75. Wayne PM, Buring JE, Eisenberg DM, Osypiuk K, Gow BJ, Davis RB, et al. Cost-effectiveness of a team-based integrative medicine approach to the treatment of back pain. J Altern Complement Med. 2019;25(S1):S138–46. pmid:30870015
- 76. Wright A, Lloyd-Davies A, Williams S, Ellis R, Strike P. Individual active treatment combined with group exercise for acute and subacute low back pain. Spine (Phila Pa 1976). 2005;30(11):1235–41. pmid:15928545
- 77. Furlong B, Etchegary H, Aubrey-Bassler K, Swab M, Pike A, Hall A. Patient education materials for non-specific low back pain and sciatica: a systematic review and meta-analysis. PLoS One. 2022;17(10):e0274527. pmid:36223377
- 78. Sharma S, Pathak A, Parker R, Costa LOP, Ghai B, Igwesi-Chidobe C. How low back pain is managed - a mixed-methods study in 32 countries. part 2 of low back pain in low- and middle-income countries series. J Orthop Sports Phys Ther. 2024;54(8):560–72.
- 79. Herman PM, McBain RK, Broten N, Coulter ID. Update of Markov model on the cost-effectiveness of nonpharmacologic interventions for chronic low back pain compared to usual care. Spine (Phila Pa 1976). 2020;45(19):1383–5. pmid:32516169